Skip to main content
OpenTrials
Completed

NCT Number: NCT05329090

Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis

Systemic vasculitis are inflammatory diseases of the blood vessels, responsible for systemic manifestations. Among the systemic vasculitis affecting small blood vessels, IgA vasculitis (IgAV) is one of the most common forms and mainly affects the skin, joints, kidneys and gastrointestinal tract. Kidney and gastrointestinal damage can be serious, causing complications and life-threatening sequelae, especially in adults. The treatment of adult-onset IgAV is still a matter of debate. Glucocorticoids have been the standard of care for inducing remission for years in severe forms of IgAV. However, not all patients achieve remission and may experience disease flares associated with increased morbidity and mortality. In addition, the cumulative side effects of glucocorticoids are also major causes of long-term adverse events and death.Rituximab (RTX), an anti-CD20 monoclonal antibody, has been shown to be spectacularly effective in inducing remission in d 'other small vascular vessels, in particular ANCA-associated vasculitis and cryoglobulinemic vasculitis, with an acceptable safety profile.

Recently, a multicenter observational study suggested that RTX was an effective and safe therapeutic option for treating relapsed and / or refractory adult IgAV.

Overall, RTX may be an effective and safe therapeutic approach in adult IgAVs, justifying the need for a prospective randomized controlled trial evaluating Rituximab as an induction of remission for adult IgAV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

IgA Vasculitis Blood Coagulation Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Hemostatic Disorders Hypersensitivity Immune Complex Diseases Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Purpura Signs and Symptoms Skin Diseases Skin Diseases, Vascular Skin Manifestations Skin and Connective Tissue Diseases Vascular Diseases Vasculitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hopital La Cavale Blanche, Brest, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biopsy-proven diagnosis of IgAV according to Chapel Hill Consensus Conference definitions
  • Patient aged of 18 years or older
  • Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an active disease defined by active manifestations attributable to IgAV
  • Patients with severe involvement of at least one organ
  • Patients within the first 21 days following initiation/increase of glucocorticoids at a dose < 1 mg/kg/day
  • Has signed an informed consent form prior to any study related procedures
  • Affiliated to a national health insurance

Exclusion criteria

  • Patients with ANCA-associated vasculitis, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,
  • Patients with IgAV in remission of the disease,
  • Patients with severe cardiac failure defined as class IV in New York Heart Association,
  • Patients with severe, uncontrolled cardiac disease,
  • Patients with acute infections or chronic active infections (including HIV, HBV or HCV),
  • Patients with active cancer or recent malignancy (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment,
  • Pregnant women and breastfeeding. Patients with childbearing potential must use reliable contraceptive methods throughout the study and at least for 12 months after the last study drug administration,
  • Patients with IgAV who have already been treated with rituximab within the previous 12 months,
  • Patients treated with immunosuppressive therapy within the last 3 months,
  • Patients with hypersensitivity to human or chimeric monoclonal antibodies,
  • Patients with contraindication to use rituximab,
  • Patients treated with any concomitant drugs contraindicated for use with the rituximab according to its SmPC,
  • Patients with contraindication to use routine care treatments (Glucocorticoids, Angiotensin-converting-enzyme (ACEis) or angiotensin receptor blockers (ARBs), dexchlorphéniramine),
  • Patients in a severely immunocompromised state,
  • Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric disorders, that could interfere with his/her compliance to protocol requirements,
  • Patients currently participating in another clinical study or 3 months prior to randomization,
  • Patients suspected not to be observant to the proposed treatments,
  • Patients unable to give written informed consent prior to participation in the study
  • Being deprived of liberty or under guardianship.

Treatment and study plan

RiTUXimab Injection

Drug

anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients

Other names: Rixathon, Truxima

Placebo

Drug

placebo experimental treatment

Other names: NaCl

Primary outcomes

  1. Rituximab efficacy

    Time frame: 180 days

    The proportion of patients alive who achieved remission with a prednisone dose of 0 mg/day at 180 days

  2. Rituximab efficacy

    Time frame: 360 days

    The proportion of patients alive who achieved remission with a prednisone dose of 0 mg/day at 360 days

Secondary outcomes

  1. Efficacy of rituximab-based regimen to induce remission

    Time frame: 180 days

    Proportion of patients with BVAS=0 (or BVAS of ≤5 if all scores were due to persistent hematuria or proteinuria) and a prednisone dose ≤5 mg/day at 180 days

  2. Efficacy of rituximab-based regimen to induce remission

    Time frame: 360 days

    Proportion of patients with BVAS=0 (or BVAS of ≤5 if all scores were due to persistent hematuria or proteinuria) and a prednisone dose ≤5 mg/day at 360 days

  3. Assessement the duration of remission

    Time frame: 360 days

    Proportion of patients achieving remission for ≥3 consecutive months over the 360 days, with BVAS=0 (or BVAS of ≤5 if all scores were due to persistent hematuria or proteinuria) and a prednisone dose ≤5 mg/day at 360 days.

  4. Assessment of patients achieving a complete or partial renal remission & renal outcome remission

    Time frame: 180 days

    Proportion of patients in complete renal and partial renal remission at 180 days (Renal parameters at 180 days compared with baseline: eGFR, daily proteinuria, hematuria, arterial hypertension, use of angiotensin converting enzyme inhibitor, occurrence of end-stage renal disease)

  5. Assessment of patients achieving a complete or partial renal remission & renal outcome remission

    Time frame: 360 days

    Proportion of patients in complete renal and partial renal remission at 360 days (Renal parameters at 360 days compared with baseline: eGFR, daily proteinuria, hematuria, arterial hypertension, use of angiotensin converting enzyme inhibitor, occurrence of end-stage renal disease)

  6. Measure of glucocorticoids dose

    Time frame: 160 days

    Area under the curve for prednisone dose at 180 days in the two treatment groups

  7. Measure of glucocorticoids dose

    Time frame: 360 days

    Area under the curve for prednisone dose at 360 days in the two treatment groups

  8. Number of participants with adverse events for the safety analyse

    Time frame: 360 days

    Adverse events, expressed as adverse events according to the CTCAE toxicity grading system per patient-year at days 180 and 360 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions, death

  9. The sequelae assessed by the Vasculitis Damage Index

    Time frame: 180 days

    The Vasculitis Damage Index in the two treatment groups

  10. The sequelae assessed by the Vasculitis Damage Index

    Time frame: 360 days

    The Vasculitis Damage Index in the two treatment groups

  11. Quality of life of patients

    Time frame: 180 days

    HAQ and SF-36 questionnaires at 180 days

  12. Quality of life of patients

    Time frame: 360 days

    HAQ and SF-36 questionnaires at 360 days

  13. Patient reported outcome

    Time frame: 360 days

    The patient-reported outcomes (PRO) including patient-reported disease activity, anxiety and depression, burden of the disease and treatment and adherence to treatment, at days 180 and 360 after randomization in the two treatment groups, and during the long-term follow-up

  14. Patient survival

    Time frame: 360 days

    Number of patient survival

Sponsors and collaborators

Lead sponsor

Hopital Foch

Other

Collaborators

  • Ministry of Health, France

Registry information

Official study title

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study

Acronym: RIGA

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 14, 2022
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.